During the past decade, Erlanger Institute for Clinical Research conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Erlanger Institute for Clinical Research" are "Arthritis, Rheumatoid" (1 trials), "Atrial Fibrillation" (1 trials), "Cardiac Resynchronization Therapy" (1 trials), "Heart Failure" (1 trials) and "Non-Small-Cell Lung Adenocarcinoma" (1 trials). Many other conditions were trialed in "Erlanger Institute for Clinical Research" in a lesser frequency.

Most popular intervention types in "Erlanger Institute for Clinical Research" are "Device" (2 trials) and "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "CRT-DX" (1 trials), "Docetaxel" (1 trials), "Ganetespib" (1 trials) and "INFINITY™ with ADAPTIS™ Technology Total Ankle System" (1 trials). Other intervention names were less common.

The vast majority of trials in "Erlanger Institute for Clinical Research" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Erlanger Institute for Clinical Research". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Erlanger Institute for Clinical Research, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Erlanger Institute for Clinical Research, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".